NeuroOne Medical Technologies Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- David A. Rosa
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 7599 Anagram Drive Eden Prairie MN United States of America 55344
- IPO Date
- Mar 15, 2018
- CIK
- 0001500198
- Website
- n1mtc.com
- Similar Companies
- Business
- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), founded in 2009 and headquartered in Eden Prairie, Minnesota, develops and commercializes minimally invasive, high-definition thin-film electrode technology for diagnostic and therapeutic neurological applications, primarily targeting epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain from failed back surgeries, and other brain-related disorders in the United States. The company's core products include Evo cortical electrodes for recording, monitoring, and stimulating brain tissue for up to 30 days; Evo sEEG electrodes for temporary subsurface brain signal recording, monitoring, and stimulation; and the OneRF radiofrequency ablation system, the world's first FDA-cleared platform for both diagnostic and therapeutic procedures using sEEG electrodes to create lesions in nervous tissue for functional neurosurgery, including trigeminal neuralgia treatment following a recent FDA 510(k) submission. It also pursues applications in spinal cord stimulation, brain stimulation, drug delivery, depression, mood disorders, incontinence, and artificial intelligence-integrated neuromodulation solutions. Recent developments encompass an expanded exclusive distribution agreement with Zimmer Biomet, granting rights to distribute the OneRF system for brain applications with a $3 million upfront payment and potential milestone payments to drive U.S. and international commercialization; a $2.65 million equity financing and $3 million credit facility in 2024 to support operations through mid-2025; filing of a 510(k) submission ahead of schedule for OneRF trigeminal nerve ablation; and appointment of neurosurgeon Dr. Parag Patil as Chief Medical Advisor to advance clinical strategies.
NeuroOne Medical Technologies Corporation (NMTC) Q2 2026 Earnings Call Transcript
Analyzing First Choice Healthcare Solutions (OTCMKTS:FCHS) & NeuroOne Medical Technologies (NASDAQ:NMTC)
NeuroOne Medical Technologies Corporation (NMTC) Discusses Platform Technology Advancements and Growth Plans for Neurological Device Applications Transcript
Brokerages Set NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) PT at $1.98
NeuroOne Medical Technologies Corporation (NMTC) Q1 2026 Earnings Call Transcript
NeuroOne Medical Technologies (NASDAQ:NMTC) versus Aclarion (NASDAQ:ACON) Head to Head Contrast
Contrasting NeuroOne Medical Technologies (NASDAQ:NMTC) and Cannlabs (OTCMKTS:CANL)
Best Momentum Stocks to Buy for January 6th
New Strong Buy Stocks for January 6th
NeuroOne Medical Technologies Corporation (NMTC) Q4 2025 Earnings Call Transcript
NeuroOne Medical Technologies Corporation - Special Call
NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025
NMTC Stock Gains as FDA Clears OneRF System for Facial Pain Treatment
NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne Medical Technologies Corporation (NMTC) Q3 2025 Earnings Call Transcript
NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time
NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office
NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System